Third Rock leads seed and Series A rounds in companies it co-founds. Our directory lists Seed and Series A coverage; the firm typically stays involved from inception through clinical milestones.

Third Rock does not publish a standard check-size range. As a company-creation biotech firm, initial commitments are sized to build teams and advance programs to key clinical inflection points — amounts vary by therapeutic area and development plan.

Third Rock is headquartered in Boston, Massachusetts, in the heart of the Cambridge-Boston biotech cluster. Portfolio companies are U.S.-focused; the firm invests nationally where scientific talent and development infrastructure align.

Third Rock focuses exclusively on biotechnology and life sciences — therapeutics, drug discovery, and related platforms. Our directory tags biotech-life-sciences. The firm is known for co-founding companies with academic and industry scientists rather than passive seed investing.

Third Rock routinely leads and often initiates rounds in companies it helps create. The model is hands-on company building — partners embed with founding teams from day one.

Directory startups listing Third Rock include Insitro, Maze Therapeutics, and BioAge Labs — see /startup/insitro, /startup/maze-therapeutics, and /startup/bioage-labs.

Third Rock's model centers on partnering with scientists and operators to build companies from scratch. Review thirdrockventures.com for the team's therapeutic focus. Warm introductions from scientific collaborators or co-investors are the standard path; the firm does not promote a public cold-pitch inbox.

See 2026-boston-vc-2026-biotech-dominance-playbook for Third Rock's role among Boston's top therapeutics-creation firms.